Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-EGFR therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody.

READ FULL ARTICLE Curated publisher From Medical Express